← 홈

ADC

32개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 32개
ADCBiologicstaleOnCusp Therapeutics, Inc.Phase 1

CUSP06 (CUSP06)

Ovarian Cancer; Solid Tumor · Ovarian Cancer

#OvarianCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleGenmabPhase 2

HuMax-AXL-ADC (Enapotamab vedotin, Enapotamab vedotin (HuMax-AXL-ADC))

Ovarian Cancer; Cervical Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 0%임상시험 1상태 ACTIVE
ADCBiologicstaleNovartis PharmaceuticalsPhase 1

HKT288 (HKT288)

Epithelial Ovarian Cancer; Renal Cell Carcinoma · Epithelial Ovarian Cancer

#EpithelialOvarianCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 DISCONTINUED
ADCBiologicstaleWhitehawk Therapeutics, Inc.Phase 1

HWK-007 (HWK-007)

Endometrial Cancer; Ovarian Cancer · EGFR

#EGFR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
ADCBiologicstaleWhitehawk Therapeutics, Inc.Phase 1

HWK-016, MUCIN-16-targeted ADC (HWK-016, MUCIN-16-targeted ADC)

PROC; Platinum Resistant Ovarian Cancer · PROC

#PROC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNextCure, Inc.Phase 1

LNCB74 (LNCB74)

Ovarian Cancer; Breast Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleAbbViePhase 1

Mirvetuximab + SL-172154 (Mirvetuximab + SL-172154)

Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer · Platinum-resistant Ovarian Cancer

#Platinum-resistantOvarianCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleShattuck Labs, Inc.Phase 1

Pegylated Liposomal Doxorubicin + SL-172154 (Pegylated Liposomal Doxorubicin + SL-172154)

Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer · Platinum-resistant Ovarian Cancer

#Platinum-resistantOvarianCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleThe First Affiliated Hospital o…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Combined with Bevacizumab)

Platinum-resistant Recurrent Ovarian Cancer (PROC) · Platinum-resistant Recurrent Ovarian Can

#Platinum-resistantRecurrentOvari#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleTakedaPhase 2

TAK-853 (TAK-853)

Ovarian Cancer; Solid Tumors · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 44%임상시험 1상태 RECRUITING
ADCBiologicstaleTubulis GmbHPhase 2

TUB-040 (TUB-040)

Ovarian Cancer; Non-small Cell Lung Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleYonsei UniversityPhase 2

Trastzumab Deruxtecan (Trastzumab Deruxtecan)

Ovarian Cancer; Ovarian Carcinoma, Recurrent · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING

2 / 2 페이지

← 이전다음 →